Candid Therapeutics clinical trials
Acquired by UCB S.A., Jun 17, 2026 · source ↗
The registry lists 7 studies whose lead sponsor is Candid Therapeutics. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Before and after it joined UCB S.A.
- First submitted before Candid Therapeutics became part of UCB S.A.
- 6
- First submitted after Candid Therapeutics became part of UCB S.A.
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Phase
- Phase 1
- 7
Registry sponsor names on this page
- Candid Therapeutics7 studies
Something wrong with this grouping? Tell us on the UCB S.A. page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All UCB S.A. studies →
- A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic DiseasesRecruitingNCT07712939Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted after Candid Therapeutics became part of UCB S.A.
- Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.
- Clinical Study of Cizutamig in Systemic Lupus ErythematosusRecruitingNCT07215663Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.
- A Clinical Study of Cizutamig in Thyroid Eye DiseaseRecruitingNCT07597200Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.
- An Open-label Study of CND261 in Seropositive Rheumatoid ArthritisActive, not recruitingNCT07052032Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.
- Absolute Bioavailability Study of Cizutamig in Healthy Adult ParticipantsCompletedNCT07236411Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.
- A Phase 1 Study of Cizutamig in IgE Mediated DiseasesWithdrawnNCT07408869Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.